TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NKGen Biotech ( (NKGN) ) has issued an update.
On July 14, 2025, NKGen Biotech entered into a strategic collaboration agreement with HekaBio K.K. to develop, manufacture, and commercialize NKGen’s SNK01 autologous NK cell therapy in Japan and other agreed territories. HekaBio will lead regulatory activities and clinical trials in Japan, leveraging the country’s expedited regulatory environment for cell therapies. The agreement includes profit-sharing terms and a buy-out option for NKGen. This partnership aims to address significant health challenges in Japan’s aging population, particularly neurodegenerative diseases like Alzheimer’s and Parkinson’s.
More about NKGen Biotech
NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focusing on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. The company is working on troculeucel, a novel NK cell therapy for neurodegenerative disorders and various cancers.
Average Trading Volume: 177,233
Technical Sentiment Signal: Sell
Current Market Cap: $12.59M
For an in-depth examination of NKGN stock, go to TipRanks’ Overview page.